Anatomical main group
B – BLUT UND BLUTBILDENDE ORGANE
49Decisions
58Patient groups
Added benefit by patient group
- Considerable3
- Minor8
- Non-quantifiable9
- Not proven38
Subgroups
- B01 ANTITHROMBOTISCHE MITTEL 8 decisions
- B02 ANTIHÄMORRHAGIKA 26 decisions
- B03 ANTIANÄMIKA 6 decisions
- B06 ANDERE HÄMATOLOGIKA 9 decisions
Decisions, newest first
- 2026-08-20DawnzeraDonidalorsenMinor
- 2026-04-02EkterlySebetralstatNon-quantifiable
- 2026-03-19AlhemoConcizumabNot proven
- 2026-03-19AlhemoConcizumabNot proven
- 2025-10-16AlhemoConcizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-10-16AlhemoConcizumabNot proven
- 2025-08-21AndembryGaradacimabConsiderable
- 2025-07-17HympavziMarstacimabNot proven
- 2025-07-17HympavziMarstacimabNot proven
- 2025-07-03CasgevyExagamglogen autotemcelNon-quantifiable
- 2025-07-03CasgevyExagamglogen autotemcelNon-quantifiable
- 2024-11-22VafseoVadadustatNot proven
- 2024-10-17ReblozylLuspaterceptMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-06-06TakhzyroLanadelumabNot proven
- 2024-02-15RefixiaNonacog beta pegolNot proven
- 2024-02-01AlprolixEftrenonacog alfaNot proven
- 2023-11-02ReblozylLuspaterceptNot proven
- 2023-11-02ReblozylLuspaterceptNot proven
- 2023-10-19HemgenixEtranacogen DezaparvovecNon-quantifiable
- 2023-09-21ReblozylLuspaterceptMinor
- 2023-08-17HemlibraEmicizumabNot proven
- 2023-03-16RoctavianValoctocogen roxaparvovecNon-quantifiable
- 2022-11-03OxbrytaVoxelotorNon-quantifiable
- 2022-05-19Mulpleo (previously Lusutrombopag Shionogi)LusutrombopagNot proven
- 2022-04-07IdelvionAlbutrepenonacog alfaNot proven
- 2022-03-03EvrenzoRoxadustatNot proven
- 2021-12-02OrladeyoBerotralstatNot proven
- 2021-11-04TakhzyroLanadelumabNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2021-01-07CabliviCaplacizumabNon-quantifiable
- 2020-12-17TavlesseFostamatinibNot proven
- 2020-02-06EsperoctTuroctocog alfa pegolNot proven
- 2019-09-05HemlibraEmicizumabNot proven
- 2019-06-20JiviDamoctocog alfa pegolNot proven
- 2019-03-22CabliviCaplacizumabNon-quantifiable
- 2018-11-01AdynoviRurioctocog alfa pegolNot proven
- 2018-09-20HemlibraEmicizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-04-19RefixiaNonacog beta pegolNot proven
- 2017-07-20AfstylaLonoctocog alfaNot proven
- 2016-09-15BriliqueTicagrelorMinor
- 2016-06-16EloctaEfmoroctocog alfaNot proven
- 2016-01-21LixianaEdoxabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-05-07NuwiqSimoctocog alfaNot proven
- 2015-02-19EliquisApixabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2014-07-03NovoEightTuroctocog alfaNot proven
- 2013-06-20EliquisApixabanMinor
- 2012-06-07EliquisApixabanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2011-12-15BriliqueTicagrelorConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
Data status: 2026-10-29